Novo Nordisk (NVO) News

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer

Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy®...

The Gross Law Firm Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline

The Gross Law Firm Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming...

Shareholders that lost money on Novo Nordisk A/S(NVO) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Shareholders that lost money on Novo Nordisk A/S(NVO) Urged to Join Class Action - Contact The Gross Law Firm...

Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join - Contact The Gross Law...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Nordisk A/S Lawsuit - NVO

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Nordisk A/S...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NVO LAWSUIT ALERT: The Gross Law Firm Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline

NVO LAWSUIT ALERT: The Gross Law Firm Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and...

The Gross Law Firm Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline

The Gross Law Firm Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming...

Novo Nordisk introduces NovoCare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy® (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients

Novo Nordisk introduces NovoCare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy® (semaglutide...

Shareholders that lost money on Novo Nordisk A/S(NVO) should contact The Gross Law Firm about pending Class Action - NVO

Shareholders that lost money on Novo Nordisk A/S(NVO) should contact The Gross Law Firm about pending Class...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights - NVO

Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before March...

Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join - Contact The Gross Law...

Novo Nordisk A/S Sued for Securities Law Violations - Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights - NVO

Novo Nordisk A/S Sued for Securities Law Violations - Contact The Gross Law Firm Before March 25, 2025 to...